Palvella Therapeutics (PVLA) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Xencor (XNCR) over the past year, gaining 98.0% versus a gain of 88.6%. Over five years, XNCR leads with a -36.0% price change compared with -61.5% for PVLA. Palvella Therapeutics is the larger company by market cap ($2.00 billion vs $1.83 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | XNCR |
|---|---|---|
| Share price | $138.77 | $24.63 |
| Market cap | $2.00B | $1.83B |
| 1-day change | +5.66% | +0.53% |
| YTD return | +32.58% | +60.88% |
| 1-year return | +97.99% | +88.59% |
| 5-year return | -61.54% | -35.98% |
| EPS (TTM) | $-4.85 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $125.58M |
| Revenue growth (YoY) | — | +13.65% |
| Net income (latest FY) | $-41.72M | $-91.92M |
| Operating margin | — | -141.35% |
| Net margin | — | -73.20% |
| 52-week high | $161.38 | $30.61 |
| 52-week low | $66.58 | $10.38 |
| Distance from 52-week high | -14.01% | -19.54% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +66.12% | +27.57% |
| Average volume | 210.72K | 1.33M |
| Shares outstanding | 14.41M | 74.35M |
| Employees | 29 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
PVLA vs XNCR FAQ
Which is bigger, Palvella Therapeutics or Xencor?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $2.00B compared with $1.83B for Xencor (XNCR).
Which stock has performed better over the past year, PVLA or XNCR?
PVLA returned +97.99% over the past 12 months, compared with +88.59% for XNCR (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.